10x Genomics' Financial Performance in Q3 2025
10x Genomics, Inc. (NASDAQ: TXG), renowned for its advancements in single-cell and spatial biology, revealed its financial results for the third quarter. This quarter's financial results underscore the company’s resilience and commitment to innovation.
Key Highlights of the Quarter
During the third quarter, the company achieved revenue of $149.0 million, marking a sequential increase, even when excluding significant one-time licensing revenue from the previous quarter. This reflects a strong ongoing interest and demand for its cutting-edge technologies.
Product Innovations
10x Genomics has advanced its product lineup significantly. The company has started the shipping of its next-generation Chromium Flex, which is designed to facilitate cost-effective, scalable single-cell analysis. This innovation empowers researchers in a multitude of biological studies.
Xenium Protein Launch
The recent launch of Xenium Protein has been a pivotal point for the company. This all-in-one spatial multiomic workflow enables simultaneous detection of RNA and proteins from the same tissue, enhancing research capabilities and efficiency.
Quarterly Financial Overview
The gross margin for the third quarter was reported at 67%, down from 70% in the same quarter of the prior year. The decrease was primarily driven by shifts in product mix and higher inventory write-downs, although lower royalty payments provided some mitigation.
Operating Costs and Losses
Operating expenses stood at $132.5 million for the quarter, down 10% from $147.9 million year-on-year. This reduction was chiefly attributed to decreased personnel and legal expenses. Consequently, the operating loss narrowed to $32.2 million from the previous year's $41.5 million.
Net Results and Future Guidance
Net loss for the quarter was $27.5 million, a notable improvement from the $35.8 million loss reported in the same period last year. 10x Genomics ended the quarter with cash and cash equivalents totaling $482.1 million, an increase of $35 million from the prior quarter, showcasing its robust financial health.
Looking Ahead
10x Genomics anticipates revenue for the fourth quarter of 2025 to range between $154 million to $158 million, signaling a strategic focus despite expected market fluctuations.
About 10x Genomics
10x Genomics is committed to enhancing the understanding of biology and advancing human health through its advanced life sciences technologies. By providing integrated research solutions, including instruments, consumables, and software, the company facilitates significant breakthroughs in areas such as oncology and immunology.
Frequently Asked Questions
What were the key financial results for 10x Genomics in Q3 2025?
In Q3 2025, 10x Genomics reported a revenue of $149 million, a notable improvement over previous quarters, despite some challenges.
What innovations did 10x Genomics introduce recently?
The company introduced the next-generation Chromium Flex platform and the Xenium Protein workflow for enhanced single-cell analysis.
How did 10x Genomics perform compared to the previous year?
The company experienced a reduction in operating losses and improved its cash reserves, showcasing a healthier financial position year-on-year.
What are the expectations for the fourth quarter?
10x Genomics expects revenue to fall between $154 million and $158 million for the fourth quarter of 2025.
How does 10x Genomics contribute to scientific advancements?
The company’s products are foundational in advancing studies of biological systems, paving the way for breakthroughs in various fields such as disease research and treatment development.
